United States
Print page content Print
Increase text size Decrease text size
Text Size


(Ceftiofur Crystalline Free Acid)

Finish the job with fewer doses


EXCEDE is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subspecies zooepidemicus (S. zooepidemicus). EXCEDE contains ceftiofur in a crystalline form, called Ceftiofur Crystalline Free Acid, or CCFA. The final product is a ready-to-use sterile suspension of CCFA in oil.

EXCEDE is the first and only licensed antibiotic for horses that offers a full course of therapy in just 2 doses. By reducing the administration requirements from 10 daily doses of a comparative antibiotic to a 2-dose regimen, EXCEDE makes the treatment process less stressful for the horse and more convenient for the veterinarian, caretaker and horse owner.

Expand All
  • FDA-approved for horses

    • The use of EXCEDE provides veterinarians peace of mind, knowing they have selected a product that has been demonstrated to be both safe and effective in horses. EXCEDE is available through veterinary prescription only


    • As the first and only sustained-release licensed antibiotic for horses, EXCEDE offers a full-course of therapy in just 2 doses for the treatment of lower respiratory tract infections caused by susceptible strains of S. zooepidemicus, the most common bacterial pathogen isolated from equine respiratory infections1-5

    Fewer doses

    • By providing 10 days of therapy in just 2 doses administered 4 days apart, versus 10 daily doses of a comparative antibiotic, veterinarians can optimize compliance. Fewer administrations means less potential for missed doses

    Benefits beyond the bottle

    • EXCEDE makes the treatment process less stressful for the horse, horse owner and caretaker. The sustained-release nature of the product means less systemic exposure to the antibiotic with comparable efficacy

    Exceptional value

    • EXCEDE provides a full course of therapy with fewer administrations, making it an affordable option
  • When injected intramuscularly, EXCEDE is continuously released into the bloodstream and is rapidly metabolized into its active form, thereby achieving a plasma level above the minimum inhibitory concentration (MIC) for S. zooepidemicus of at least 4 days for the first injection and up to 10 days after 2 injections, administered 96 hours apart. This results in long-acting and safe therapeutic levels. Dosage is 3 mg/lb (6.6mg/kg) with a maximum of 20mL per injection site.


    • EXCEDE Sterile Suspension is available in 100 mL vials.
    1. Clark C, Greenwood S, Boison JO, et.al. Bacterial isolates from equine infections in western Canada (1998-2003). Can Vet J 2008;49:153-160.
    2. Freedom of Information Summary, EXCEDE Sterile Suspension/Ceftiofur Crystalline Free Acid Horses, NADA 141-209, December 16, 2009, Pfizer Animal Health.
    3. Mazan MR. Equine infectious respiratory disease: a review. Pfizer Animal Health Tech Bull, Sept 2009.
    4. Raidal SL. Equine pleuropneumonia. Br Vet J 1995;151:233-262.
    5. Warner AE. Bacterial pneumonia in adult horses. In: Smith BP, ed. Large animal internal medicine, 3rd ed. St Louis: CV Mosby; 2002:491-496.

     Summer Horse Health Care Guide

     Excede Quick Tip

Important Safety Information:

People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to EXCEDE. EXCEDE is contraindicated in animals with known allergy to ceftiofur or the the β-lactam group (penicillins and cephalosporins) of antimicrobials. Do not use in horses intended for human consumption. The administration of antimicrobials in horses under conditions of stress may be associated with diarrhea, which may require appropriate veterinary therapy.

For more safety information, refer to the full prescribing information and material safety data sheet.